Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Weber

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibitionRobert Ferguson, Vylyny Chat, Leah Morales, et al.
PDA Journal of Pharmaceutical Science and Technology|December 18, 2019
Practical Applications of Biofluorescent Particle Counting in Environmental Monitoring InvestigationsAditya Prasad, Annett Milling, James Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world dataJustin C Moser, Shailender Bhatia, Asim Amin, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibitionRobert Ferguson, Vylyny Chat, Leah Morales, et al.
PDA Journal of Pharmaceutical Science and Technology|December 18, 2019
Practical Applications of Biofluorescent Particle Counting in Environmental Monitoring InvestigationsAditya Prasad, Annett Milling, James Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world dataJustin C Moser, Shailender Bhatia, Asim Amin, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Pageof 11